Literature DB >> 10833386

Expression and purification of recombinant human indoleamine 2, 3-dioxygenase.

T K Littlejohn1, O Takikawa, D Skylas, J F Jamie, M J Walker, R J Truscott.   

Abstract

Indoleamine 2,3-dioxygenase, the first and rate-limiting enzyme in human tryptophan metabolism, has been implicated in the pathogenesis of many diseases. The human enzyme was expressed in Escherichia coli EC538 (pREP4) as a fusion protein to a hexahistidyl tag and purified to homogeneity in terms of electrophoretic and mass spectroscopic analysis, by a combination of phosphocellulose and nickel-agarose affinity chromatography. The yield of the fusion protein was 1.4 mg per liter of bacterial culture with an overall recovery of 56% from the crude extract. When the culture medium was supplemented with 7 microM hemin, the purified protein contained 0.8 mol of heme per mole of enzyme and exhibited an absorption spectrum consistent with the ferric form of hemoprotein. The pI value of the recombinant enzyme was 7.09 compared with 6.9 for the native enzyme. This was as expected from the addition of the hexahistidyl tag. Similar to the native enzyme, the recombinant enzyme required methylene blue and ascorbic acid for enzyme activity and oxidized not only l-tryptophan but also d-tryptophan and 5-hydroxy-l-tryptophan. The molecular activities for these substrates and their K(m) values were similar to those of the native enzyme, indicating that the addition of the hexahistidyl tag did not significantly affect catalytic activity. The recombinant protein can therefore be used to investigate properties of the native enzyme. This will aid the development of specific inhibitors of indoleamine 2,3-dioxygenase, which may be effective in halting disease progression. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833386     DOI: 10.1006/prep.2000.1214

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  21 in total

1.  Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening.

Authors:  Hongao Zhang; Wei Liu; Zhihong Liu; Yingchen Ju; Mengyang Xu; Yue Zhang; Xinyu Wu; Qiong Gu; Zhong Wang; Jun Xu
Journal:  Medchemcomm       Date:  2018-03-01       Impact factor: 3.597

2.  Biochemical mechanisms leading to tryptophan 2,3-dioxygenase activation.

Authors:  Junsuo S Li; Qian Han; Jianmin Fang; Menico Rizzi; Anthony A James; Jianyong Li
Journal:  Arch Insect Biochem Physiol       Date:  2007-02       Impact factor: 1.698

3.  Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase.

Authors:  Farhad Forouhar; J L Ross Anderson; Christopher G Mowat; Sergey M Vorobiev; Arif Hussain; Mariam Abashidze; Chiara Bruckmann; Sarah J Thackray; Jayaraman Seetharaman; Todd Tucker; Rong Xiao; Li-Chung Ma; Li Zhao; Thomas B Acton; Gaetano T Montelione; Stephen K Chapman; Liang Tong
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-29       Impact factor: 11.205

Review 4.  Role of dendritic cell metabolic reprogramming in tumor immune evasion.

Authors:  Michael P Plebanek; Michael Sturdivant; Nicholas C DeVito; Brent A Hanks
Journal:  Int Immunol       Date:  2020-06-26       Impact factor: 4.823

5.  The ternary complex of PrnB (the second enzyme in the pyrrolnitrin biosynthesis pathway), tryptophan, and cyanide yields new mechanistic insights into the indolamine dioxygenase superfamily.

Authors:  Xiaofeng Zhu; Karl-Heinz van Pée; James H Naismith
Journal:  J Biol Chem       Date:  2010-04-26       Impact factor: 5.157

6.  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Authors:  William P Malachowski; Maria Winters; James B DuHadaway; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Maisha Rahman; Eesha Sheikh; Judith M LaLonde; Syun-Ru Yeh; George C Prendergast; Alexander J Muller
Journal:  Eur J Med Chem       Date:  2015-12-17       Impact factor: 6.514

7.  Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

Authors:  Paul Gaspari; Tinku Banerjee; William P Malachowski; Alexander J Muller; George C Prendergast; James DuHadaway; Shauna Bennett; Ashley M Donovan
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

8.  Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase.

Authors:  Gilles Ferry; Caroline Ubeaud; Pierre-Hervé Lambert; Sophie Bertin; Francis Cogé; Pascale Chomarat; Philippe Delagrange; Bernard Serkiz; Jean-Paul Bouchet; Roger J W Truscott; Jean A Boutin
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

9.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Authors:  Sanjeev Kumar; Daniel Jaller; Bhumika Patel; Judith M LaLonde; James B DuHadaway; William P Malachowski; George C Prendergast; Alexander J Muller
Journal:  J Med Chem       Date:  2008-07-30       Impact factor: 7.446

10.  Evolution of vertebrate indoleamine 2,3-dioxygenases.

Authors:  Hajime Julie Yuasa; Miwa Takubo; Ayumi Takahashi; Tetsuo Hasegawa; Hiroshi Noma; Tomohiko Suzuki
Journal:  J Mol Evol       Date:  2007-11-17       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.